TRML Share Price Performance
Recent TRML News & Updates
No updates
Tourmaline Bio, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.23
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Tourmaline Bio, Inc. Competitors
About TRML
- Founded
- 2021
- Employees
- 74
- CEO
- WebsiteView website
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company’s development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
U.S. Market Performance
- 7 Days: -0.3%
- 3 Months: 14.2%
- 1 Year: 15.7%
- Year to Date: 8.0%
In the last week, the market has stayed flat, however the Energy sector stood out, gaining 3.9%. Meanwhile, the market is actually up 17% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading